--- canonical_name: ACD856 alternate_names: NeuroRestore ACD856, ACD-856 canonical_topic: ACD856 for Health & Longevity short_topic_lc: acd856 creation_date: 2026-0904-1534 creator_ai_fullname: Opus 5 ep_keywords: Trk-PAMs, Trk Positive Allosteric Modulators, Neurotrophin Receptor Modulators --- # ACD856 for Health & Longevity
Evidence Review created on 09/04/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** NeuroRestore ACD856, ACD-856 ## Motivation ACD856 is an experimental oral compound built to strengthen the brain's own growth-signaling system. Nerve cells depend on a small family of proteins that keep them alive, help them build connections, and support memory. ACD856 does not supply those proteins. It makes the docking points they act on respond more strongly to whatever signal is already there. The approach draws interest because this signaling weakens with age and is reduced in several brain disorders. The compound came from an unlikely starting point. A screening program run by a small Swedish company found that two veterinary antiparasitic medicines could boost this signaling, and chemists reshaped them into a molecule suited to the human brain. It has since been given to healthy volunteers in early studies, and preparation for testing in patients is under way. This review examines what is established about ACD856: how it is thought to work, what the laboratory and animal work shows, what the early human studies did and did not measure, and where the evidence runs out. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists the most useful in-depth sources on ACD856 and on the approach it represents — positive allosteric modulation (amplifying a receptor's response to its own natural signal) of the Trk receptors (tropomyosin receptor kinases, the docking points for the brain's neurotrophin growth proteins). * [Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/39204102/) - Forsell et al., 2024 Reviews the whole positive allosteric modulator class for Alzheimer's disease, placing ACD856 beside Eisai's TrkA-selective E2511 and explaining why earlier neurotrophin protein therapies failed. * [ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics](https://pubmed.ncbi.nlm.nih.gov/38353689/) - Nilsson et al., 2024 The first-in-human report: an intravenous microdose used to predict half-life, then oral doses from 1 to 150 mg with a food-effect arm. The clearest source on absorption and elimination. * [Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects](https://pubmed.ncbi.nlm.nih.gov/37874100/) - Önnestam et al., 2023 Seven days of dosing in 24 volunteers, with sampling of the fluid bathing the brain and brain-wave recording. The only human dataset showing the compound reaches the brain and changes measurable brain activity. * [Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction](https://pubmed.ncbi.nlm.nih.gov/34440640/) - Dahlström et al., 2021 The discovery paper. Documents the 25,000-compound screen, the veterinary antiparasitic starting points, receptor potency values, and the animal memory experiments that everything later written about this compound rests on. * [Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/37446337/) - Parrado Fernandez et al., 2023 The neuroprotection case: cell survival against amyloid-β (the plaque-forming protein of Alzheimer's disease) and energy deprivation, raised growth protein in aged mice, and a week-long antidepressant effect. **A note on these sources.** All five were authored by scientists employed by or affiliated with AlzeCure Pharma AB, the company that owns ACD856 and stands to profit from its adoption. That financial interest is disclosed in each paper and applies to every clinical and preclinical dataset cited anywhere in this review; no independent group has published original data on the compound. No professional society, advocacy organization, or guideline body has taken a position on ACD856, so no such party is cited here on any side of the question. Separately, none of the six priority expert platforms (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has covered ACD856 or Trk receptor modulation, which is why no item from those platforms appears above. ## Grokipedia * [ACD856](https://grokipedia.com/page/ACD856) A single consolidated overview of discovery, mechanism, trial history, and funding, useful as an orientation map before reading the primary papers. ## Examine No Examine article exists for ACD856. Examine.com covers dietary supplements and nutrition compounds and does not typically cover investigational prescription-track drug candidates, which is the category ACD856 falls into. ## ConsumerLab No ConsumerLab article exists for ACD856. ConsumerLab independently tests marketed dietary supplements and does not typically cover prescription medications or investigational drug candidates, so an entry would not be expected. ## Systematic Reviews No systematic reviews or meta-analyses for ACD856 were found on PubMed as of September 4, 2026. Neither side of the trade-off is represented: there is no systematic review of the claimed cognitive benefit and none of the principal risk, because the compound has never been studied in patients. ## Mechanism of Action Trk receptors (tropomyosin receptor kinases — TrkA, TrkB and TrkC) are the docking points on nerve cells for the neurotrophins, growth proteins that include nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). When a neurotrophin binds, the receptor pairs up and switches on three cascades: Ras–ERK1/2 (a growth and gene-expression pathway), PI3K–Akt (a cell-survival pathway) and PLCγ (which governs calcium release and synaptic strength). ACD856 is a positive allosteric modulator: it binds away from the natural docking site and amplifies whatever signal is already present rather than activating the receptor itself. It binds just inside the cell membrane and raises TrkA's maximum catalytic rate, apparently by speeding the kinase cycle rather than neurotrophin binding. Selectivity is pan-Trk: half-maximal potentiation occurs near 0.38 µM at TrkA and 0.30 µM at TrkB, with TrkC also amplified, while related growth-factor receptors (IGF1R, FGFR1) respond far less ([Dahlström et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34440640/)). Pharmacologically, it has almost complete oral bioavailability (the share of a dose reaching the bloodstream), a plasma half-life near 20 hours, and is cleared entirely by metabolism — no unchanged compound reaches urine, and the responsible enzymes are unpublished ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/)). Peak concentration arrives within 30–45 minutes; cerebrospinal fluid reaches 37–120% of unbound plasma ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). Two mechanistic readings compete. Because the compound only amplifies existing signaling, one view predicts failure where neurotrophin supply is exhausted, as in advanced disease; the other holds residual tone suffices, citing the response in aged animals. ## Historical Context & Evolution The parent molecules were never intended for the brain. Toltrazuril and its active metabolite ponazuril are triazinetrione antiprotozoal agents used in veterinary medicine — ponazuril treats equine protozoal myeloencephalitis (a parasitic spinal-cord disease of horses). A screen of roughly 25,000 compounds by AlzeCure Pharma, published in 2021, tested for potentiation of neurotrophin signaling and found both triazinetriones among the top hits ([Dahlström et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34440640/)). Ponazuril was taken forward as the clinical candidate ACD855, then abandoned: its human half-life was too long for practical dosing. ACD856 is the chemically optimized successor. The wider effort to treat cognitive decline by restoring neurotrophin signaling is older and instructive. Recombinant nerve growth factor delivered into the brain, and later encapsulated cell implants releasing it into the basal forebrain (the memory-related cell group at the brain's base), were tested in Alzheimer's disease. Those studies produced measurable biology — cerebrospinal fluid marker changes that tracked receptor imaging and cognitive scores — but were small, open-label cohorts never powered to demonstrate benefit ([Eyjolfsdottir et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27389402/)). Delivery was the acknowledged obstacle: the proteins do not cross from blood into brain, and systemic exposure produced pain. That history is often summarized as a dead end. The more accurate reading is that a delivery problem was never separated from a target problem, and small orally available modulators were built specifically to test the two apart. Whether the target was ever wrong remains open; no adequately powered efficacy trial of any Trk-directed agent has yet reported. ## Expected Benefits Grades below describe the class of evidence behind each claim, not the size of the claim. For someone tracking cognitive resilience deliberately, the practical point is that this compound currently has no human efficacy data at all. ### High 🟩 🟩 🟩 No benefit reaches High: no human clinical endpoint and no validated clinical surrogate has been measured for ACD856 in any trial, let alone in more than one — the completed studies recorded only safety, drug levels in the body and brain-wave activity. ### Medium 🟩 🟩 No benefit reaches Medium: no single trial has measured a cognitive, functional or mood outcome in people, and no observational data on the compound exist. ### Low 🟩 ### Speculative 🟨 #### Reversal of Age-Related Memory Decline A single dose restored memory performance in 18-month-old mice to the level seen in 2-month-old mice. Evidence is animal behavioral work only ([Dahlström et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34440640/)); no human cognitive endpoint has been measured. #### Neuroprotection Against Amyloid-β and Energy-Deprivation Toxicity In cultured primary cortical neurons the compound limited cell death from amyloid-β and from energy withdrawal, and raised brain-derived neurotrophic factor. The basis is in-vitro only ([Parrado Fernandez et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37446337/)). #### Anti-Inflammatory and Immunomodulatory Activity In animal models of Alzheimer's disease and aging the compound lowered raised inflammatory signaling proteins, among them interleukin-6 and interleukin-1β ([AlzeCure Pharma, 2024](https://www.alzecurepharma.se/en/alzecure-presents-new-anti-inflammatory-data-with-neurorestore-acd856-at-the-alzheimers-conference-ctad/)). The basis is developer-reported preclinical data only. #### Antidepressant-Like Activity Repeated dosing reduced immobility in the rodent forced-swim test, with the effect lasting up to seven days after the last dose ([Parrado Fernandez et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37446337/)). No human mood endpoint has been measured. #### Enhanced Synaptic Plasticity and Cholinergic Tone Trk potentiation facilitated long-term potentiation (durable strengthening of a synapse) in rat hippocampal slices. The related compound ACD855 also raised hippocampal acetylcholine by 40% ([Dahlström et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34440640/)); both are animal findings. #### Improved Insulin Sensitivity in Obese Animals The developer reports that ACD856 raised insulin sensitivity in obese animals, and a genetic study of the same pathway proposes it as an obesity target ([AlzeCure Pharma, April 2025](https://www.alzecurepharma.se/en/new-scientific-article-in-nature-linking-the-potential-use-of-neurorestore-acd856-for-the-treament-of-obesity/)). Animal and genetic data only. #### Central Target Engagement Detected on Brain Recordings Daily dosing at 30–90 mg produced dose-dependent electroencephalographic shifts — higher relative theta power, lower fast alpha and beta ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). This is an unvalidated biomarker, not a cognitive outcome. ## Benefit-Modifying Factors * **BDNF Val66Met variant:** a common change in the brain-derived neurotrophic factor gene that reduces activity-dependent release of the protein and has been weakly and inconsistently linked to smaller hippocampal volume ([Harrisberger et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24674929/)). Carriers may have less signal for the compound to amplify. * **APOE4 status:** the apolipoprotein E ε4 variant is the strongest common genetic risk factor for Alzheimer's disease and shapes who would be dosed. No ACD856 data are stratified by it, so any effect on response is unmeasured. * **Baseline neurotrophin tone:** the mechanism amplifies an existing signal rather than creating one. Where nerve growth factor and brain-derived neurotrophic factor supply is already depleted, as in advanced neurodegeneration, the theoretical ceiling on benefit is lower. * **Sex:** brain-derived neurotrophic factor expression is estrogen-sensitive, so a sex difference is biologically plausible. The microdose study enrolled only men; the seven-day study included both sexes but no sex-stratified analysis has been published. * **Pre-existing conditions:** the developer targets cognitive impairment in Alzheimer's disease, Parkinson's disease, traumatic brain injury and sleep apnea. All completed studies enrolled healthy volunteers, so benefit in any of these states is untested. * **Age:** the largest preclinical effect appeared in aged animals, where neurotrophin signaling has declined most. Human dosing has so far been confined to healthy adults, with no reported data in people over 65. ## Potential Risks & Side Effects Total human exposure is roughly 90 healthy volunteers across four short studies. Nothing below should be read as a settled safety profile. ### High 🟥 🟥 🟥 No risk reaches High: no adverse event or laboratory finding has been reproduced as drug-attributable in more than one controlled trial, and no clinical endpoint has been recorded in people with disease. ### Medium 🟥 🟥 No risk reaches Medium: the published single-dose and multiple-dose reports state that no adverse event was treatment-emergent or dose-related, so no single trial establishes a drug-attributable clinical outcome, and no observational dataset exists. ### Low 🟥 #### Transient Pancreatic Enzyme Elevation Two participants in the seven-day multiple-dose study had transient rises in lipase or amylase (enzymes released by an irritated pancreas) that returned to normal at reassessment. No abdominal symptoms or pancreatitis were reported. The observation is uncontrolled and from one small study ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). **Magnitude:** 2 of 24 participants, roughly 8%, showed an isolated lipase or amylase rise that returned to normal at reassessment; no fold-elevation figure was published. #### Transient Liver Enzyme Elevation One participant in the intravenous microdose study — an active weightlifter — had transient liver enzyme rises graded severe on one occasion five days after dosing, judged by the investigator as possibly treatment-related. The subject was asymptomatic; the observation is uncontrolled and from a six-person study ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/)). **Magnitude:** 1 of 6 participants in the microdose study, on a single occasion five days after dosing; no fold-elevation figure beyond the severe severity grade was published. #### Mild to Moderate Adverse Events Without a Dose Relationship Across single oral doses of 1–150 mg and seven days of dosing up to 90 mg daily, reported events were mostly mild and occasionally moderate, most often headache, and were not classed as treatment-emergent or dose-related ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/); [Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). Total human exposure remains small. **Magnitude:** Events were mostly mild, a minority moderate, and showed no dose relationship across 1–150 mg single doses or 10–90 mg daily for seven days; the published reports give no per-event incidence figure. ### Speculative 🟨 #### Theoretical Tumor-Promoting Potential Trk signaling drives growth in cancers carrying fusions of the NTRK genes (which encode these receptors) ([Cocco et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30333516/)). Potentiating the same receptors is a mechanistic concern; no tumor signal exists. #### Increased Pain Sensitivity Nerve growth factor acting at TrkA sensitizes pain fibers; blocking it relieves osteoarthritis pain ([Gao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35494494/)). Amplifying that pathway could plausibly heighten pain; no such signal appeared in volunteers. #### Brain-Wave Slowing of Uncertain Meaning ⚠️ Conflicted Dosing raised theta power. The developer reads this as target engagement; the same pattern marks cognitive decline in dementia ([Olğun et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38217438/)). Net reading: the biomarker is uninterpretable. #### Mood or Behavioral Activation Trk potentiation drives antidepressant-like effects in rodents, so mood, anxiety or sleep changes are plausible. Anxiety, depression and suicidality questionnaires in the seven-day study showed no signal ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). ## Risk-Modifying Factors * **Unmapped metabolizing enzymes:** clearance is entirely metabolic, but the enzymes and any polymorphisms governing them are unpublished. Variants in whichever pathway dominates could raise or lower exposure without warning, and no pharmacogenetic guidance exists. * **Baseline pancreatic and liver enzymes:** the laboratory signals seen in humans were isolated lipase, amylase and liver enzyme rises. A baseline already at the upper end of the reference range removes the headroom needed to interpret a later change. * **Sex:** no sex-stratified safety analysis has been published. The microdose study was male-only, so half the human safety database on intravenous exposure carries no information about women. * **Pre-existing conditions:** prior pancreatitis, chronic pain states, and any personal history of NTRK-fusion-driven cancer are the theoretical concerns. Every completed study excluded significant disease, so none of these interactions has been observed. * **Age:** all participants were healthy adults, and no results have been reported for people over 65 — the group the compound is intended for. Age-related changes in metabolism and organ reserve are therefore unmeasured. ## Key Interactions & Contraindications * **No human interaction study exists:** every entry below is inferred from mechanism or from class behavior, not measured. Severity is therefore "caution, unquantified" throughout unless stated otherwise. * **Enzyme-mediated exposure shifts:** strong inhibitors or inducers of drug-metabolizing enzymes (ketoconazole, ritonavir, grapefruit juice, rifampicin, carbamazepine) could raise or lower exposure unpredictably. Caution; the mitigating action is to avoid strong modulators during dosing. * **Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine — drugs that raise acetylcholine):** preclinical work suggests Trk potentiation adds to their effect. Caution — additive cholinergic excess: nausea, diarrhea and bradycardia (a slow heart rate). Mitigation: introduce one agent at a time, with pulse monitoring. * **Antidepressants (fluoxetine and other serotonin reuptake inhibitors, which raise serotonin levels; ketamine):** their behavioral effects run through TrkB signaling ([Madjid et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37394539/)). Caution — additive mood activation. Mitigation: mood and sleep scores tracked during the first weeks. * **Anti-nerve-growth-factor antibodies (tanezumab, fasinumab):** directly opposing pharmacology. These would be expected to blunt TrkA-mediated effects. Caution; separation in time does not help, since antibody half-lives run to weeks. * **Drugs associated with pancreatitis (valproate, azathioprine, GLP-1 receptor agonists — glucagon-like peptide-1 medicines for diabetes and weight loss, such as semaglutide):** theoretical additive concern given the observed enzyme rises. Caution; mitigation is baseline and on-treatment lipase measurement. * **Over-the-counter medications:** no studies exist. Sedating antihistamines (diphenhydramine, doxylamine), which also block acetylcholine, would be expected to oppose the cholinergic effect. Caution; mitigation is to substitute a non-sedating antihistamine such as loratadine. * **Supplements acting on the same pathway:** 7,8-dihydroxyflavone, curcumin, omega-3 fatty acids and *Hericium erinaceus* are each proposed to raise neurotrophin signaling. Additive effect is plausible and unquantified. Caution; mitigation is to add one at a time. * **Other interventions:** aerobic exercise raises circulating neurotrophin levels ([Walsh & Tschakovsky, 2018](https://pubmed.ncbi.nlm.nih.gov/29775542/)), and sleep extension is proposed to do the same. The interaction is potentiating and benign; no separation or dose adjustment is indicated. **Populations who should avoid ACD856:** * Anyone outside a registered clinical trial — the compound is not approved by any regulator and no supply of verified identity and purity exists. * People with a history of acute pancreatitis, or baseline lipase or amylase above 3× the upper limit of normal (the highest value a laboratory reports as normal). * People with moderate or severe liver impairment (Child-Pugh Class B or C, a standard grading of liver failure severity), since clearance is entirely metabolic. * People with active or previously treated cancer driven by an NTRK gene fusion. * Women who are pregnant or breastfeeding, and adults under 18 — no reproductive or pediatric data exist. ## Risk Mitigation Strategies * **Trial-only access:** obtaining the compound through a registered study is the single largest risk reduction available, because it removes exposure to unidentified gray-market material of unknown identity, purity and dose. * **Baseline pancreatic panel:** lipase and amylase are measured before the first dose and again at day 8, mirroring the phase 1 schedule. This is the only laboratory abnormality yet seen and needs a personal reference point to interpret. * **Starting at the low end of the studied range:** doses of 10 mg daily were studied alongside 30 and 90 mg with no dose-related signal. Beginning low preserves the ability to detect an idiosyncratic response. * **Single morning dose:** a half-life near 20 hours means once-daily morning dosing reaches steady state by day 6 without stacking peaks, limiting the peak-concentration exposure that drives most early adverse events. * **Structured mood and sleep tracking:** a weekly anxiety and depression questionnaire is recorded during the first month, as the phase 1 studies did. This is the mitigation for the plausible mood-activation risk from Trk potentiation. * **No stacking of pathway-active supplements:** 7,8-dihydroxyflavone, high-dose curcumin and *Hericium erinaceus* are held during the first month. This prevents an unquantified additive effect from being mistaken for the compound's own. * **Escalation no faster than the studied schedule:** each dose level is held for at least seven days before increasing, matching the interval at which steady state was confirmed. Faster escalation risks exposure above any level yet tested in humans. ## Therapeutic Protocol * **No established protocol:** ACD856 is investigational. Nothing below is a clinical regimen — the only administered schedules are those written into the phase 1 protocols by the sponsor. * **Studied regimen:** an oral solution given once daily in the morning, at 10, 30 or 90 mg, for seven consecutive days, with steady state reached before day 6 ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). * **Single-dose range explored:** oral doses from 1 mg to 150 mg were given as single administrations, with a separate food-effect arm at 40 mg ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/)). * **Competing approach — TrkA-selective modulation:** Eisai's E2511 modulates TrkA alone rather than all three receptors, and has reported preclinical disease-modifying effects, per a narrative review of the class ([Forsell et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39204102/)). Neither selectivity strategy is established as superior. * **Competing approach — direct receptor agonists:** small molecules such as 7,8-dihydroxyflavone activate TrkB directly rather than amplifying an existing signal, and carry a different theoretical profile in tissue where neurotrophin supply is exhausted. * **Who developed each approach:** the pan-Trk modulator line came from Gunnar Nordvall, Pontus Forsell and Johan Sandin at AlzeCure Pharma, with Karolinska Institutet collaborators; E2511 came from Eisai's neurology program. * **Best time of day:** morning. All studies dosed in the morning, peak concentration arrives within 30–45 minutes, and the brain-wave shift is measurable within hours of the dose. * **Half-life:** approximately 20 hours after both intravenous and oral administration ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/)), unchanged at steady state, with accumulation ratios near 1.6 for peak and 1.9 for total exposure ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). * **Single versus split dosing:** a single daily dose was used throughout. The long half-life makes splitting unnecessary, and no split-dose data exist to support it. * **Food:** food lowered and delayed peak concentration but had little effect on half-life or overall exposure ([Nilsson et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38353689/)). Trials dosed fasted; taking it with food is unlikely to change total exposure meaningfully. * **Genetic polymorphisms:** none is validated for this compound. BDNF Val66Met and APOE4 are the plausible candidates for stratifying response, and metabolizing-enzyme variants for exposure, but no pharmacogenetic data have been published. * **Sex-based differences:** the microdose study enrolled men only; the seven-day study enrolled both sexes. No sex difference in exposure, tolerability or brain-wave response has been reported either way. * **Age:** all participants were healthy adults; no dose has been characterized in people over 65, despite that being the intended population. Age-adjusted dosing therefore has no evidentiary basis. * **Baseline biomarkers:** no baseline measure has been shown to predict response. The brain-wave change was dose-dependent rather than baseline-dependent in the two highest cohorts. * **Pre-existing conditions:** every study excluded significant disease. How Alzheimer's disease, Parkinson's disease or traumatic brain injury alters exposure or response is entirely unknown. ## Discontinuation & Cycling * **Intended duration:** the compound is positioned as a chronic daily treatment for a progressive condition, with a claimed disease-modifying component. No human study has run longer than the phase Ib schedule, so long-term use is aspirational. * **Withdrawal effects:** none reported. Follow-up in the seven-day study extended past the last dose with no rebound in mood, anxiety or brain-wave measures described ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). * **Washout:** with a half-life near 20 hours, plasma exposure falls below a tenth of steady state within about four days, and cerebrospinal fluid follows plasma closely. * **Tapering:** no taper was used in any study and none appears necessary given the absence of withdrawal effects and the absence of receptor-blocking activity. * **Cycling:** untested. The rodent antidepressant effect persisted around seven days after dosing stopped, which is the only hint that intermittent schedules might retain activity — it has not been examined in humans. ## Sourcing and Quality * **Not commercially available:** ACD856 is an investigational compound owned by a single company. It cannot be legitimately purchased, and no pharmacy, compounder or supplement manufacturer supplies it. * **Gray-market material carries no assurance:** powders offered online under this designation have no verified identity, purity or content. The published chemical structure is not fully disclosed, so independent analytical confirmation is not straightforward. * **The veterinary precursor is not a substitute:** ponazuril, sold as an equine antiprotozoal paste, is the earlier candidate ACD855. It was dropped from human development for an impractically long half-life and is not an equivalent. * **Third-party testing programs do not apply:** the compound is not a dietary supplement, so no supplement certification scheme covers it. The quality controls that exist are the sponsor's own good-manufacturing-practice batches. * **Formulation:** all human studies used an oral solution. No tablet or capsule has been validated, and the food effect on peak concentration is specific to that solution. ## Practical Considerations * **Time to effect:** unknown for any clinical outcome. Brain-wave changes were measurable within days of starting, but no cognitive, functional or mood endpoint has ever been measured, so no meaningful time-to-benefit exists. * **Common pitfall — confusing it with ponazuril:** the veterinary precursor is cheap and obtainable, which invites substitution. It is a different molecule, carrying the half-life flaw that ended its human development. * **Common pitfall — reading target engagement as efficacy:** the brain-wave signature shows the compound reaches and acts on the brain. It says nothing about whether memory or function improves. * **Regulatory status:** investigational. Not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any indication, so no off-label route exists — off-label use presupposes an approval somewhere. * **Cost and accessibility:** no price exists; access is limited to trial participation in Sweden and, prospectively, the planned patient study. This is the binding constraint on the compound today. * **Payer incentives favor an oral small molecule:** approved anti-amyloid antibodies cost roughly $26,000–$32,000 yearly plus infusion visits and repeat brain imaging. Insurers and national health systems therefore have a structural reason to favor cheap oral alternatives, which can bias guideline and funding decisions. ## Interaction with Foundational Habits * **Sleep:** direction is uncertain and probably indirect. The brain-wave shift is toward slower frequencies, which overlaps with drowsiness patterns, yet no sedation or insomnia was reported at any dose. The developer explicitly targets cognitive impairment arising from sleep apnea. Practical point: morning dosing keeps peak concentration far from bedtime. * **Nutrition:** a direct absorption interaction. Food lowers and delays peak concentration without materially changing total exposure or half-life. No nutrient depletion is described. Practical point: consistency matters more than fasting — taking it the same way each day keeps peak concentration comparable across days. * **Exercise:** potentiating, through a shared mechanism. Aerobic exercise raises circulating brain-derived neurotrophic factor, and the compound amplifies signaling at the receptor that protein acts on ([Walsh & Tschakovsky, 2018](https://pubmed.ncbi.nlm.nih.gov/29775542/)). Practical point: training raises the signal the compound is designed to multiply, so the two are complementary rather than redundant. * **Stress management:** indirect and plausible. Chronic stress lowers brain-derived neurotrophic factor expression, and the same pathway carries the antidepressant effect seen in rodents. Prolactin (a pituitary hormone sensitive to this pathway) was tracked without a signal ([Önnestam et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37874100/)). Practical point: stress reduction protects the endogenous tone the compound depends on. ## Monitoring Protocol & Defining Success Because no dosing occurs outside a clinical trial, the sensible protocol is the one the phase 1 investigators used. Baseline testing established organ function and a reference point for the pathway being modulated: pancreatic enzymes, alanine aminotransferase (ALT, a liver enzyme released when liver cells are stressed), estimated glomerular filtration rate (eGFR, a calculated measure of how fast the kidneys clear blood), prolactin, a resting electroencephalogram (a recording of the brain's electrical activity), and mood and suicidality questionnaires. On treatment the cadence was fixed: pancreatic and liver enzymes on day 1, day 4 and day 8, then at follow-up two weeks after the last dose; questionnaires weekly; brain-wave recording at steady state. A longer outpatient schedule would repeat the panel at 4 weeks, 12 weeks, then every 6–12 months. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Serum lipase | 13–60 U/L | The one laboratory signal seen in humans | Released by an irritated pancreas. Conventional assays often report up to 160 U/L as normal, so the functional target is tighter. Fasting draw, paired with amylase. | | Serum amylase | 30–110 U/L | Confirms or refutes a lipase finding | Less pancreas-specific than lipase and also rises with salivary gland problems. Drawn in the same tube as lipase. | | ALT | 10–26 U/L (men), 10–19 U/L (women) | Clearance is entirely metabolic, so liver stress matters | Conventional upper limits run to 40–55 U/L; functional targets are tighter. Intense exercise in the 48 hours before the draw raises it. | | eGFR | ≥90 mL/min/1.73 m² | Establishes organ reserve before dosing | Conventional cut-off for "normal" is 60. No unchanged compound reaches urine, so a change here is unlikely to be drug-related. Normal hydration applies. | | Prolactin | 3–13 ng/mL (men), 3–20 ng/mL (non-pregnant women) | Carried forward from the trial safety panel | Conventional upper limit is about 25 ng/mL. Mid-morning draw, 1–2 hours after waking; stress and nipple stimulation raise it. | | Serum brain-derived neurotrophic factor | No established target exists; track the change from the individual's own baseline instead | Reflects the pathway being amplified | Blood levels correlate poorly with brain levels, and serum and plasma values differ several-fold. Comparability requires the same laboratory, tube type and time of day each draw. | Qualitative markers matter here, because no validated cognitive endpoint exists for this compound: * **Cognitive clarity:** word-finding, mental arithmetic under time pressure, and the ease of holding several threads at once, rated weekly on a fixed scale. * **Memory:** recall of the previous day's conversations and reading, which is closer to the animal finding than any speed measure. * **Mood and drive:** activation, irritability and initiative, tracked because the same pathway carries the rodent antidepressant effect. * **Sleep quality:** time to fall asleep and number of awakenings, given the unresolved meaning of the brain-wave shift. * **Pain sensitivity:** any new or worsened aching or skin tenderness, tracked because amplifying TrkA is theoretically pain-promoting. ## Emerging Research * **Completed multiple-dose study with a brain-wave endpoint:** [NCT05077501](https://clinicaltrials.gov/study/NCT05077501), a phase 1 study in 24 healthy participants dosed at 10, 30 or 90 mg daily for seven days. Primary endpoint was adverse-event frequency; it produced the first human evidence that the compound reaches the brain. * **Completed single ascending dose study:** [NCT05077631](https://clinicaltrials.gov/study/NCT05077631), a phase 1 study in 56 healthy participants covering 1–150 mg with a food-effect arm. It established near-complete oral bioavailability and dose-proportional exposure. * **Completed microdose study:** [NCT05783830](https://clinicaltrials.gov/study/NCT05783830), an early phase 1 study in six participants given 0.1 mg intravenously to measure half-life before any oral dosing — a de-risking step after the predecessor compound failed on that parameter. * **Higher-dose phase Ib study completed 2026:** the sponsor reported in June 2026 that repeated dosing above previously studied levels was well tolerated with expected rises in blood and cerebrospinal fluid ([AlzeCure Pharma, 2026](https://www.alzecurepharma.se/en/positive-results-from-the-phase-ib-clinical-study-of-neurorestore-acd856-under-development-for-alzheimers/)). No registry entry exists for it. * **Planned phase II study in patients:** funded by a €2.5 million European Innovation Council grant awarded in 2025 ([AlzeCure Pharma, 2025](https://www.alzecurepharma.se/en/alzecure-receives-eu-grant-for-phase-2-clinical-trial-of-neurorestore-acd856-for-alzheimers-disease/)). This would be the first study with a cognitive endpoint and the first in people with disease. No registration number has been posted. * **Competing candidate in the same class:** E2511, a TrkA-selective modulator, is reviewed alongside ACD856 by [Forsell et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39204102/). A readout there would strengthen or undercut the whole receptor-modulation premise independently of this compound. * **Risk that the biomarker does not translate:** earlier neurotrophin-directed attempts implanted nerve-growth-factor-releasing devices into the brain and produced measurable biological change without ever reaching an efficacy readout ([Eyjolfsdottir et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27389402/)). The same gap could open here. * **Long-term Trk potentiation and tumor surveillance:** no study has examined whether sustained receptor amplification affects tumor risk in people, a question that class biology raises directly ([Cocco et al., 2018](https://pubmed.ncbi.nlm.nih.gov/30333516/)). Any chronic-use program will have to address it. ## Conclusion ACD856 is an experimental oral compound that makes brain cells more responsive to their own growth signals rather than supplying those signals directly. It was found by screening thousands of molecules and refining two veterinary medicines. The case for it is currently made entirely in cells, in animals, and in one brain-recording measurement. In laboratory work it protected neurons from stress, raised the growth protein it acts on, and restored memory performance in old mice to that of young ones. In healthy volunteers it was taken up well, reached the brain in measurable amounts, and changed brain-wave patterns in a dose-related way. What it has never done is improve memory, mood or function in any person, because no study has yet measured those things. The safety picture is thin rather than reassuring: a small number of healthy volunteers, short exposures, two isolated laboratory changes, and no signal attributable to the compound. Every dataset comes from the company that owns it, which discloses that interest but has no independent counterpart. The brain-wave finding is read by that company as evidence of reaching the target, while the same pattern is a marker of decline in dementia — a genuine unresolved ambiguity. For someone tracking cognitive resilience deliberately, the position today is a well-characterized mechanism, a compound that reaches the brain, and no evidence in people that either one turns into better memory, mood or function. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**